This study included 75 cases; 39 with gynecological cancer of different types, stages, and grades (14 ovarian, 11 endometrial, 9 cervical, and 5 vulvovaginal); 23 patients with benign gynecological diseases and 13 normal healthy controls. Serum TPS was estimated using the ELISA kit supplied by Beki Diagnostic AB, Bromma, Sweden. The results of the present study revealed that serum TPS was significantly elevated in cancer patients followed by those with benign diseases. When the cutoff values were adjusted to 137 and 101 U/L, we obtained sensitivities of 56.4% and 82.1% at specifities of 100% and 85%, respectively. The benign diseases group had false positive rates of 13% and 34.8%, respectively. When considering tumor site, vulvo vaginal cancer showed the highest sensitivity (80%) followed by cervical (66.7%), ovarian (50%), and lastly endometrial cancer (45.5%). Serial measurement of TPS was shown to be of important value in the post-surgical follow-up of cancer patients.
CrombachG., WürtzH.Carcinoma of the female genital tract. In: LüthgensM., SchlegelG. eds. Clinical use of the tumor marker system CEA-TPA.Leonberg: Tumor Diagnostic Verlag, 1989; 51–63.
2.
MokhtarN.Female genital system tumors. In: Cancer pathology registry 1985-1990, National Cancer Institute.Cairo University, 1991; 45–52.
3.
DevineP.L., YarkerJ.Y., FongK.M.Serum markers CASA, CEA, CYFRA21-1, MSA, NSE, TPA and TPS in lung cancer.Int J Oncol1994; 4: 1129–35.
4.
OehrP.TPS, TPA and keratins; similarities and difference (meeting abstract). The 9th International Conference on Human Tumor Markers, Vienna, Austria, 1992; Sept. 6-9.
5.
Van DalenA.TPS in breast cancer - A comparative study with carcinoembryonic antigen and CA 15-3.Tumor Biol1992 a; 13: 10.
6.
BremerK., RichterK., BremerG., KibingF.Clinical value of TPS in breast cancer patients. In: KlapdorR. ed. Tumor associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.München, Bern, Wien, New York: W Zuckschwerdt Verlag, 1992; 52.
7.
EskelinenM., HippelainenM., SalmelaE., PaajnenH., AlhavaE., SyrjanenK.A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.Anticaner Res1992; 12: 2033–6.
8.
MansourO., MotawiT., KhaledH., El-AhmadyO.Clinical value of thymidine kinase and tissue polypeptide specific antigens in breast cancer.Disease Markers1993; 11: 171–7.
MarrinkF., OosteromR., BonfrerH.M.G., SchroderF.H., MensinkJ.A.Tissue polypeptide specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.Eur J Cancer1993; 29: 570–1.
11.
TarleM., KovacickK., KastelanM.Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.Anticancer Res1993; 13: 215–8.
12.
El-AhmadyO., EissaSanaa, Gamal El-DinA., Van DalenA., Van CauberghR.D.TPS in serum and urine of Egyptian bladder cancer patients.Oncology Reports1994; 1: 519–21.
13.
MarinoP., BuccheriG., PreatoniA., FerrignoD., LuperiniA.C., PravettoniG.Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors.Int J Biol Markers1992; 7: 65–7.
14.
BrowningM.C.K., McFarlaineN.P.Serum TPS concentrations in malignant disease. In: KlapedorR. ed. Tumor associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.München, Bern, Wien, New York: W Zuckschwerdt Verlag, 1992; 208–12.
15.
BhatavdekarJ.M., PatelD.D., VoraH.H., BalarD.Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study.Anticancer Res1993; 13: 237–40.
16.
KhalifaA., HalimH., El-AhmadyO.The value of tumor markers in bronchial carcinoma.J Tumor Marker Oncol1988; 3(4): 417.
17.
OehrP., LiuQ.TPS: Biology of new tumor marker using the M3-epitope. 2nd International Conference of the Mediterranean Society of Tumor Marker Oncology, Nice, France, 1991; Nov. 16-19.
18.
BjörklundB.Tumor markers TPA, TPA-S and cytokeratins.Tumor Diagnostik und Therapie1992; 13: 78.
19.
HalimA.B., El-AhmadyO., El-SokkaryF., MotawiT.How can you choose a biological marker panel for gynecological cancer?The Cancer Journal1993; 6(4): 201–7.
20.
DörfflerP., CaffierH.Comparison of the clinical value of tumor markers TPS and CA 125 regarding ovarian carcinomas. In: KlapdorR. ed. Tumor associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.München, Bern, Wien, New York: W Zuckschwerdt Verlag, 1992; 103–6.
21.
GitschG., KainzC.H., JouraE., FrohlichB., BieglmayerC.H.Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow-up of stage III cervical cancer.Anticancer Res1992; 12: 1247–50.
22.
LiuQ., NapM., OehrP.The immunohistochemical relation between keratins, TPA and TPS in human tissues. In: KlapdorR. ed. Tumor associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.München, Bern, Wien, New York: W Zuckschwerdt Verlag, 1992; 517.
23.
HalimA.B., El-AhmadyO., HamzaS., Aboul-ElaM., OehrP.Serum TPS versus TPA in Egyptian bladder cancer patients.Int J Biol Markers1993; 8(4): 221–6.
24.
Van DalenA.Quantitative analysis of tumor marker changes in breast cancer. The 9th International Conference on Human Tumor Markers, Vienna, Austria, 1992; Sept. 6-9.
25.
KornekG., PfeffelF., SchenkT., BauerJ., ScheithauerW.TPS for monitoring chemotherapeutic response in gastrointestinal cancer. The 9th International Conference on Human Tumor Markers, Vienna, Austria, 1992; Sept. 6-9.
26.
Van DalenA.Is TPS able to assist in decision making in breast cancer? In: KlapdorR. ed. Tumor associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.München, Bern, Wien, New York: W Zuckschwerdt Verlag, 1992; 86.
27.
LiuQ., NapM., OehrP.The immunohistochemical relation between TPS, Ki67 and proliferation. In: KlapdorR. ed. Tumor associated antigen, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties.München, Bern, Wien, New York: W Zuckschwerdt Verlag, 1992; 214.
